Fosun Pharma has announced that the company and its controlling shareholder, Fosun International Limited, have submitted a joint application to the Stock Exchange of Hong Kong (SEHK) pursuant to Practice Note 15, seeking approval for the proposed spin-off listing. The SEHK has confirmed that Fosun Pharma and Fosun International may proceed with the proposed spin-off.
On June 26, 2026, the subsidiary, Fosun Antigen, submitted a listing application to the SEHK via its joint sponsors. The application seeks the listing of, and permission to deal in, Fosun Antigen's H shares on the Main Board of the SEHK.